Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses
- First Online:
Recent results suggest that treatment with the atypical antipsychotics clozapine and olanzapine is associated with increased insulin and lipid levels.
The aim of the present study was to investigate potential relationships between insulin or other hormones related to glucose–insulin homeostasis or lipids and steady-state serum concentrations of clozapine or olanzapine in patients on therapeutic doses.
Thirty-four patients, diagnosed with schizophrenia or related psychoses according to the DSM-IV criteria and treated with clozapine (n=18) or olanzapine (n=16), were studied. Median treatment time with the antipsychotics was 5.3 years (range 0.5–16.3 years). Fasting blood samples for insulin, C-peptide, insulin-like growth factor I, insulin-like growth factor binding protein-1, leptin, glucose and lipids were analyzed and investigated in relation to the patients' drug serum concentrations.
Hyperinsulinemia was found in 30–60% of the patients, hyperglycemia in 10–30%, hyperlipidemia in 40–60% and hyperleptinemia in 10–20%. Moreover, levels of insulin, C-peptide and triglycerides correlated positively to the clozapine serum concentration and to the ratio of olanzapine to N-desmethylolanzapine concentrations. In contrast, levels of C-peptide, leptin and blood glucose were inversely correlated to the serum concentration of the metabolite N-desmethylolanzapine.
Metabolic abnormalities (i.e. hyperinsulinemia, hyperlipidemia and hyperleptinemia) and insulin resistance were associated with both clozapine and olanzapine treatments. Levels of insulin and triglycerides increased by increasing clozapine serum concentration and by increasing ratio of olanzapine to N-desmethylolanzapine; the last due to the metabolite N-desmethylolanzapine probably having an inverse effect to the main compound olanzapine. Thus, the metabolic abnormalities induced by these two drugs are clozapine-concentration dependent in clozapine-treated patients, and ratio of olanzapine to N-desmethylolanzapine-concentration dependent in olanzapine-treated patients.
KeywordsAntipsychotic agents Clozapine Olanzapine Adverse effects Insulin Lipids
- Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475Google Scholar
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, WashingtonGoogle Scholar
- Bang P, Eriksson U, Sara V, Wivall I-L, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 124:620–629PubMedGoogle Scholar
- Baxter RC (1991) Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand 372:107–114Google Scholar
- Budavari S, O'Neil MJ, Smith A, Heckelman PE, Kinneary JF (eds) (1996) The Merck Index. An encyclopedia of chemicals, drugs, and biologicals, 12th edn. Merck, Rahway, New Jersey, pp 411, 1170Google Scholar
- Gauch R, Michaelis W (1971)The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine (clozapine) in mice, dogs and human subjects. Farm Ed Prat 26:667–681Google Scholar
- Girard J (1997) Is leptin the link between obesity and insulin resistance ? Diabetes Metab 23:16–24Google Scholar
- Hartman ML (1996) Physiological regulators of growth hormone secretion. In: Juul A, Jørgensen JOL (eds) Growth hormone in adults: Physiological and clinical aspects, 1st edn. Cambridge University Press, New York, pp 5–219Google Scholar
- Kissebah AH (1992) Insulin actions in vivo: insulin and lipoprotein metabolism. In: Alberti KG, DeFronzo H, Keen H, Zimmet P (eds) International textbook of diabetes mellitus. Wiley, Chichester, pp 439–457Google Scholar
- Madsbad S, Hartling SG, Faber OK (1997) C-peptide and proinsulin. In: Alberti KG, Zimmet P, DeFronzo RA, Keen H (eds) International textbook of diabetes mellitus, 2nd edn. Wiley, Chichester, pp 355–381Google Scholar
- Olefsky JM (1997) Insulin resistance. In: Porte D, Sherwin RS (eds) Diabetes mellitus, 5th edn. Appleton and Lange, Stamford, pp 513–552Google Scholar
- Powell DR, Lee PD, Suwanichkul A (1994) Similarities in the regulation of hIGFBP-1 and PEPCK gene expression. In: Baxter RC, Gluckman PD, Rosenfeld RG (eds) The insulin-like growth factors and their regulatory proteins. Elsevier, Amsterdam, pp 141–150Google Scholar
- Woods SC, Kaiyala K, Porte D, Schwartz MW (1997) Food intake and energy balance. In: Porte D, Sherwin RS (eds) Diabetes mellitus, 5th edn. Appleton and Lange, Stamford, pp 175–192Google Scholar